Seeking Alpha

Raptor Pharmaceuticals (RPTP +4.4%) pokes out a tidy gain after the firm announces that it...

Raptor Pharmaceuticals (RPTP +4.4%) pokes out a tidy gain after the firm announces that it signed a R&D agreement with the National Institutes of Diabetes and Digestive and Lidney Diseases to conduct a Phase 2b clinical trial in Q1 on the efficacy of its RP104 tablet.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs